CADL
Candel Therapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$12.78
−1.46%0
Insider buys (3m)
3
Insider sells (3m)
-$389.9K
Net value (3m)
+52.8%
Price return (3m)
Form 4 filings
| Date | Insider | Activity | Shares | Price |
|---|---|---|---|---|
| Aug 19, 2026 | Tyagarajan Seshu · officer: Chief Technology Officer | Sale | 7,000 | $12 |
| Jul 8, 2026 | Sims Mark E. · officer: Chief Commercial Officer | A-Award | 285,000 | $10 |
| Jul 1, 2026 | PAPA JOSEPH C · director | A-Award | 1,331 | $10 |
| Jul 1, 2026 | Loggia Nicoletta · director | A-Award | 381 | $10 |
| Jul 1, 2026 | Barone Francesca · officer: Chief Scientific Officer | Sale | 23,447 | $10 |
| Jul 1, 2026 | Tyagarajan Seshu · officer: Chief Technology Officer | Sale | 7,000 | $10 |
| Jul 1, 2026 | Manning Paul B · director | A-Award | 2,199 | $10 |
| Jun 24, 2026 | PAPA JOSEPH C · director | A-Award | 32,000 | $9.08 |
| Jun 24, 2026 | Martell Christopher · director | A-Award | 32,000 | $9.08 |
| Jun 24, 2026 | Nabel Gary J. · director | A-Award | 32,000 | $9.08 |
| Jun 24, 2026 | Gaeta Renee · director | A-Award | 32,000 | $9.08 |
| Jun 24, 2026 | Loggia Nicoletta · director | A-Award | 32,000 | $9.08 |
| Jun 24, 2026 | Benz Edward J. JR · director | A-Award | 32,000 | $9.08 |
| Jun 24, 2026 | Radhakrishnan Maha · director | A-Award | 32,000 | $9.08 |
| Jun 24, 2026 | Manning Paul B · director | A-Award | 32,000 | $9.08 |
| Jun 24, 2026 | Nguyen Diem · director | A-Award | 32,000 | $9.08 |
| Apr 2, 2026 | Manning Paul B · director | A-Award | 4,618 | $4.90 |
| Apr 2, 2026 | Loggia Nicoletta · director | A-Award | 779 | $4.90 |
| Apr 2, 2026 | PAPA JOSEPH C · director | A-Award | 2,795 | $4.90 |
| Feb 26, 2026 | Manning Paul B · director | Purchase | 550,458 | $5.45 |
| Jan 28, 2026 | Tak Paul Peter · director, officer: Chief Executive Officer | A-Award | 629,000 | $6.01 |
| Jan 28, 2026 | Nichols William Garrett · officer: Chief Medical Officer | A-Award | 136,500 | $6.01 |
| Jan 28, 2026 | Tyagarajan Seshu · officer: Chief Technology Officer | A-Award | 154,000 | $6.01 |
| Jan 28, 2026 | Barone Francesca · officer: Chief Scientific Officer | A-Award | 232,000 | $6.01 |
| Jan 28, 2026 | Schoch Charles · officer: Chief Financial Officer | A-Award | 232,000 | $6.01 |
| Jul 30, 2025 | Nichols William Garrett · officer: Chief Medical Officer | M-Exempt | 937 | $1.29 |
| Jul 30, 2025 | Nichols William Garrett · officer: Chief Medical Officer | Sale | 937 | $6.98 |
| Jul 2, 2025 | Nichols William Garrett · officer: Chief Medical Officer | Sale | 781 | $5.04 |
| Jul 2, 2025 | Nichols William Garrett · officer: Chief Medical Officer | M-Exempt | 781 | $1.29 |
| Jun 26, 2025 | Schoch Charles · officer: Chief Financial Officer | A-Award | 5,353 | $4.67 |
Institutional positioning
13F filings over the trailing two quarters
New 39Increased 43Reduced 22Sold out 111
| Filer | Action | Shares | Filed |
|---|---|---|---|
| FMR LLC | Increased | 10,987,017 | May 15, 2026 |
| RTW INVESTMENTS, LP | New Position | 6,422,018 | May 15, 2026 |
| ACORN CAPITAL ADVISORS, LLC | Increased | 3,497,948 | May 15, 2026 |
| BLACKROCK, INC. | Increased | 3,109,042 | May 13, 2026 |
| SATURN V CAPITAL MANAGEMENT LLC | New Position | 2,896,588 | May 15, 2026 |
| PORTOLAN CAPITAL MANAGEMENT, LLC | Increased | 2,894,325 | May 15, 2026 |
| VANGUARD CAPITAL MANAGEMENT LLC | New Position | 2,462,757 | May 15, 2026 |
| VESTAL POINT CAPITAL, LP | New Position | 1,125,000 | May 15, 2026 |
| MILLENNIUM MANAGEMENT LLC | New Position | 1,060,086 | May 15, 2026 |
| GEODE CAPITAL MANAGEMENT, LLC | Increased | 1,035,435 | May 15, 2026 |
| HALTER FERGUSON FINANCIAL INC. | Reduced | 904,051 | Apr 28, 2026 |
| STATE STREET CORP | Increased | 818,558 | May 15, 2026 |
| HEIGHTS CAPITAL MANAGEMENT, INC | New Position | 775,000 | May 15, 2026 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | Increased | 420,273 | May 15, 2026 |
| SANDS CAPITAL VENTURES, LLC | Unchanged | 405,837 | May 8, 2026 |
Insider activity from SEC Form 4; institutional positioning from 13F filings · Latest filing Aug 19, 2026